{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T17:25:43Z","timestamp":1708968343279},"reference-count":55,"publisher":"American Institute of Mathematical Sciences (AIMS)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MBE"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p xml:lang=\"fr\">&lt;abstract&gt;\n\t\t\t&lt;p&gt;Skin cutaneous melanoma (SKCM) is one of the most malignant forms of skin cancer, characterized by its high metastatic potential and low cure rate in advanced stages. Despite advancements in clinical therapies, the overall cure rate for SKCM remains low due to its resistance to conventional treatments. Inflammation is associated with the activation and regulation of inflammatory responses and plays a crucial role in the immune system. It has been implicated in various physiological and pathological processes, including cancer. However, the mechanisms of inflammasome activation in SKCM remain largely unexplored. In this study, we quantified the expression level of six inflammasome-related gene sets using transcriptomic data from SKCM patients. As a result, we found that inflammasome features were closely associated with various clinical characteristics and served as a favorable prognostic factor for patients. A functional enrichment analysis revealed the oncogenic role of inflammasome features in SKCM. Unsupervised clustering was applied to identify immune clusters and inflammatory subtypes, revealing a significant overlap between immune cluster 4 and SKCM subtype 2. The CASP1, GSDMD, NLRP3, IL1B, and IL18 features could predict immune checkpoint blockade therapy response in various SKCM cohorts. In conclusion, our study highlighted the significant association between the inflammasome and cancer treatment. Understanding the role of inflammasome signaling in SKCM pathology can help identify potential therapeutic targets and improve patient prognosis.&lt;\/p&gt;\n\t\t&lt;\/abstract&gt;<\/jats:p>","DOI":"10.3934\/mbe.2023881","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T03:09:13Z","timestamp":1698894553000},"page":"19912-19928","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the link between inflammasomes and skin cutaneous melanoma: Insights into expression patterns and immunotherapy response prediction"],"prefix":"10.3934","volume":"20","author":[{"given":"Yu","family":"Sheng","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Harbin Medical University, Heilongjiang 150001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Harbin Medical University, Heilongjiang 150001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Heilongjiang Provincial Hospital, Heilongjiang 150036, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Harbin Medical University, Heilongjiang 150001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2321","reference":[{"key":"key-10.3934\/mbe.2023881-1","doi-asserted-by":"publisher","unstructured":"D. Schadendorf, D. E. Fisher, C. Garbe, J. E. Gershenwald, J. Grob, A. Halpern, et al., Melanoma, <i>Nat. Rev. Dis. Primers<\/i>, <b>1<\/b> (2015), 15003. https:\/\/doi.org\/10.1038\/nrdp.2015.3","DOI":"10.1038\/nrdp.2015.3"},{"key":"key-10.3934\/mbe.2023881-2","doi-asserted-by":"publisher","unstructured":"A. M. M. Eggermont, A. Spatz, C. Robert, Cutaneous melanoma, <i>Lancet<\/i>, <b>383<\/b> (2014), 816\u2013827. https:\/\/doi.org\/10.1016\/S0140-6736(13)60802-8","DOI":"10.1016\/S0140-6736(13)60802-8"},{"key":"key-10.3934\/mbe.2023881-3","doi-asserted-by":"publisher","unstructured":"G. C. Leonardi, L. Falzone, R. Salemi, A. Zanghi, D. A. Spandidos, J. A. McCubrey, et al., Cutaneous melanoma: From pathogenesis to therapy (Review), <i>Int. J. Oncol.<\/i>, <b>52<\/b> (2018), 1071\u20131080. https:\/\/doi.org\/10.3892\/ijo.2018.4287","DOI":"10.3892\/ijo.2018.4287"},{"key":"key-10.3934\/mbe.2023881-4","doi-asserted-by":"publisher","unstructured":"D. J. Shah, R. S. Dronca, Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma, <i>Mayo Clin. Proc.<\/i>, <b>89<\/b> (2014), 504\u2013519. https:\/\/doi.org\/10.1016\/j.mayocp.2014.02.002","DOI":"10.1016\/j.mayocp.2014.02.002"},{"key":"key-10.3934\/mbe.2023881-5","doi-asserted-by":"publisher","unstructured":"P. P. Centeno, V. Pavet, R. Marais, The journey from melanocytes to melanoma, <i>Nat. Rev. Cancer<\/i>, <b>23<\/b> (2023), 372\u2013390. https:\/\/doi.org\/10.1038\/s41568-023-00565-7","DOI":"10.1038\/s41568-023-00565-7"},{"key":"key-10.3934\/mbe.2023881-6","doi-asserted-by":"publisher","unstructured":"F. R. Greten, S. I. Grivennikov, Inflammation and cancer: Triggers, mechanisms, and consequences, <i>Immunity<\/i>, <b>51<\/b> (2019), 27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025","DOI":"10.1016\/j.immuni.2019.06.025"},{"key":"key-10.3934\/mbe.2023881-7","doi-asserted-by":"publisher","unstructured":"J. Amin, D. Boche, S. Rakic, What do we know about the inflammasome in humans?, <i>Brain Pathol.<\/i>, <b>27<\/b> (2017), 192\u2013204. https:\/\/doi.org\/10.1111\/bpa.12479","DOI":"10.1111\/bpa.12479"},{"key":"key-10.3934\/mbe.2023881-8","doi-asserted-by":"publisher","unstructured":"F. Martinon, K. Burns, J. Tschopp, The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta, <i>Mol. Cell<\/i>, <b>10<\/b> (2002), 417\u2013426. https:\/\/doi.org\/10.1016\/s1097-2765(02)00599-3","DOI":"10.1016\/s1097-2765(02)00599-3"},{"key":"key-10.3934\/mbe.2023881-9","doi-asserted-by":"publisher","unstructured":"T. Strowig, J. Henao-Mejia, E. Elinav, R. Flavell, Inflammasomes in health and disease, <i>Nature<\/i>, <b>481<\/b> (2012), 278\u2013286. https:\/\/doi.org\/10.1038\/nature10759","DOI":"10.1038\/nature10759"},{"key":"key-10.3934\/mbe.2023881-10","doi-asserted-by":"publisher","unstructured":"R. Karki, S. M. Man, T. Kanneganti, Inflammasomes and Cancer, <i>Cancer Immunol. Res.<\/i>, <b>5<\/b> (2017), 94\u201399. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0269","DOI":"10.1158\/2326-6066.CIR-16-0269"},{"key":"key-10.3934\/mbe.2023881-11","doi-asserted-by":"publisher","unstructured":"V. A. K. Rathinam, S. K. Vanaja, K. A. Fitzgerald, Regulation of inflammasome signaling, <i>Nat. Immunol.<\/i>, <b>13<\/b> (2012), 333\u2013342. https:\/\/doi.org\/10.1038\/ni.2237","DOI":"10.1038\/ni.2237"},{"key":"key-10.3934\/mbe.2023881-12","doi-asserted-by":"publisher","unstructured":"N. Kayagaki, I. B. Stowe, B. L. Lee, K. O'Rourke, K. Anderson, S. Warming, et al., Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling, <i>Nature<\/i>, <b>526<\/b> (2015), 666\u2013671. https:\/\/doi.org\/10.1038\/nature15541","DOI":"10.1038\/nature15541"},{"key":"key-10.3934\/mbe.2023881-13","doi-asserted-by":"publisher","unstructured":"J. Shi, Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, et al., Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death, <i>Nature<\/i>, <b>526<\/b> (2015), 660\u2013665. https:\/\/doi.org\/10.1038\/nature15514","DOI":"10.1038\/nature15514"},{"key":"key-10.3934\/mbe.2023881-14","doi-asserted-by":"publisher","unstructured":"Y. Li, G. Nanayakkara, Y. Sun, X. Li, L. Wang, R. Cueto, et al., Analyses of caspase-1-regulated transcriptomes in various tissues lead to identification of novel IL-1\u03b2-, IL-18- and sirtuin-1-independent pathways, <i>J. Hematol. Oncol.<\/i>, <b>10<\/b> (2017), 40. https:\/\/doi.org\/10.1186\/s13045-017-0406-2","DOI":"10.1186\/s13045-017-0406-2"},{"key":"key-10.3934\/mbe.2023881-15","doi-asserted-by":"publisher","unstructured":"C. Jin, R. A. Flavell, Molecular mechanism of NLRP3 inflammasome activation, <i>J. Clin. Immunol.<\/i>, <b>30<\/b> (2010), 628\u2013631. https:\/\/doi.org\/10.1007\/s10875-010-9440-3","DOI":"10.1007\/s10875-010-9440-3"},{"key":"key-10.3934\/mbe.2023881-16","doi-asserted-by":"publisher","unstructured":"L. Chen, L. Wang, N. Tsang, D. M. Ojcius, C. Chen, C. Ouyang, et al., Tumour inflammasome-derived IL-1beta recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma, <i>EMBO Mol. Med.<\/i>, <b>4<\/b> (2012), 1276\u20131293. https:\/\/doi.org\/10.1002\/emmm.201201569","DOI":"10.1002\/emmm.201201569"},{"key":"key-10.3934\/mbe.2023881-17","doi-asserted-by":"publisher","unstructured":"M. S. Carlino, J. Larkin, G. V. Long, Immune checkpoint inhibitors in melanoma, <i>Lancet<\/i>, <b>398<\/b> (2021), 1002\u20131014. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X","DOI":"10.1016\/S0140-6736(21)01206-X"},{"key":"key-10.3934\/mbe.2023881-18","doi-asserted-by":"publisher","unstructured":"D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, <i>Nat. Rev. Cancer<\/i>, <b>12<\/b> (2012), 252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","DOI":"10.1038\/nrc3239"},{"key":"key-10.3934\/mbe.2023881-19","doi-asserted-by":"publisher","unstructured":"M. A. Curran, W. Montalvo, H. Yagita, J. P. Allison, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, <i>Proc. Natl. Acad. Sci.<\/i>, <b>107<\/b> (2010), 4275\u20134280. https:\/\/doi.org\/10.1073\/pnas.0915174107","DOI":"10.1073\/pnas.0915174107"},{"key":"key-10.3934\/mbe.2023881-20","doi-asserted-by":"publisher","unstructured":"E. M. Van Allen, D. Miao, B. Schilling, S. A. Shukla, C. Blank, L. Zimmer, et al., Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, <i>Science<\/i>, <b>350<\/b> (2015), 207\u2013211. https:\/\/doi.org\/10.1126\/science.aad0095","DOI":"10.1126\/science.aad0095"},{"key":"key-10.3934\/mbe.2023881-21","doi-asserted-by":"publisher","unstructured":"C. N. Owen, X. Bai, T. Quah, S. N. Lo, C. Allayous, S. Callaghan, et al., Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma, <i>Ann. Oncol.<\/i>, <b>32<\/b> (2021), 917\u2013925. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.204","DOI":"10.1016\/j.annonc.2021.03.204"},{"key":"key-10.3934\/mbe.2023881-22","doi-asserted-by":"publisher","unstructured":"J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. D. Lao, et al., Five-year survival with combined nivolumab and ipilimumab in advanced melanoma, <i>New Engl. J. Med.<\/i>, <b>381<\/b> (2019), 1535\u20131546. https:\/\/doi.org\/10.1056\/NEJMoa1910836","DOI":"10.1056\/NEJMoa1910836"},{"key":"key-10.3934\/mbe.2023881-23","doi-asserted-by":"publisher","unstructured":"J. Larkin, C. D. Lao, W. J. Urba, D. F. McDermott, C. Horak, J. Jiang, et al., Efficacy and safety of nivolumab in patients with braf v600 mutant and braf wild-type advanced melanoma: A pooled analysis of 4 clinical trials, <i>JAMA Oncol.<\/i>, <b>1<\/b> (2015), 433\u2013440. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1184","DOI":"10.1001\/jamaoncol.2015.1184"},{"key":"key-10.3934\/mbe.2023881-24","doi-asserted-by":"publisher","unstructured":"J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. J. Grob, C. L. Cowey, C. D. Lao, et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, <i>New Engl. J. Med.<\/i>, <b>373<\/b> (2015), 23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","DOI":"10.1056\/NEJMoa1504030"},{"key":"key-10.3934\/mbe.2023881-25","doi-asserted-by":"publisher","unstructured":"J. Hou, M. Karin, B. Sun, Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?, <i>Nat. Rev. Clin. Oncol.<\/i>, <b>18<\/b> (2021), 261\u2013279. https:\/\/doi.org\/10.1038\/s41571-020-00459-9","DOI":"10.1038\/s41571-020-00459-9"},{"key":"key-10.3934\/mbe.2023881-26","doi-asserted-by":"publisher","unstructured":"B. Theivanthiran, K. S. Evans, N. C. DeVito, M. Plebanek, M. Sturdivant, L. P. Wachsmuth, et al., A tumor-intrinsic PD-L1\/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy, <i>J. Clin. Invest.<\/i>, <b>130<\/b> (2020), 2570\u20132586. https:\/\/doi.org\/10.1172\/JCI133055","DOI":"10.1172\/JCI133055"},{"key":"key-10.3934\/mbe.2023881-27","doi-asserted-by":"publisher","unstructured":"C. I. Diakos, K. A. Charles, D. C. McMillan, S. J. Clarke, Cancer-related inflammation and treatment effectiveness, <i>Lancet Oncol.<\/i>, <b>15<\/b> (2014), 493\u2013503. https:\/\/doi.org\/10.1016\/S1470-2045(14)70263-3","DOI":"10.1016\/S1470-2045(14)70263-3"},{"key":"key-10.3934\/mbe.2023881-28","doi-asserted-by":"publisher","unstructured":"M. Ju, J. Bi, Q. Wei, L. Jiang, Q. Guan, M. Zhang, et al., Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer, <i>Briefings Bioinf.<\/i>, <b>22<\/b> (2021), 345. https:\/\/doi.org\/10.1093\/bib\/bbaa345","DOI":"10.1093\/bib\/bbaa345"},{"key":"key-10.3934\/mbe.2023881-29","doi-asserted-by":"publisher","unstructured":"R. Karki, T. Kanneganti, Diverging inflammasome signals in tumorigenesis and potential targeting, <i>Nat. Rev. Cancer<\/i>, <b>19<\/b> (2019), 197\u2013214. https:\/\/doi.org\/10.1038\/s41568-019-0123-y","DOI":"10.1038\/s41568-019-0123-y"},{"key":"key-10.3934\/mbe.2023881-30","doi-asserted-by":"publisher","unstructured":"Q. Liang, J. Wu, X. Zhao, S. Shen, C. Zhu, T. Liu, et al., Establishment of tumor inflammasome clusters with distinct immunogenomic landscape aids immunotherapy, <i>Theranostics<\/i>, <b>11<\/b> (2021), 9884\u20139903. https:\/\/doi.org\/10.7150\/thno.63202","DOI":"10.7150\/thno.63202"},{"key":"key-10.3934\/mbe.2023881-31","doi-asserted-by":"publisher","unstructured":"J. Lonsdale, J. Thomas, M. Salvatore, R. Phillips, E. Lo, S. Shad, et al., The Genotype-Tissue Expression (GTEx) project, <i>Nat. Genet.<\/i>, <b>45<\/b> (2013), 580\u2013585. https:\/\/doi.org\/10.1038\/ng.2653","DOI":"10.1038\/ng.2653"},{"key":"key-10.3934\/mbe.2023881-32","doi-asserted-by":"publisher","unstructured":"M. J. Goldman, B. Craft, M. Hastie, K. Repecka, F. McDade, A. Kamath, et al., Visualizing and interpreting cancer genomics data via the Xena platform, <i>Nat. Biotechnol.<\/i>, <b>38<\/b> (2020), 675\u2013678. https:\/\/doi.org\/10.1038\/s41587-020-0546-8","DOI":"10.1038\/s41587-020-0546-8"},{"key":"key-10.3934\/mbe.2023881-33","doi-asserted-by":"publisher","unstructured":"M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, et al., limma powers differential expression analyses for RNA-sequencing and microarray studies, <i>Nucleic Acids Res.<\/i>, <b>43<\/b> (2015), 47. https:\/\/doi.org\/10.1093\/nar\/gkv007","DOI":"10.1093\/nar\/gkv007"},{"key":"key-10.3934\/mbe.2023881-34","doi-asserted-by":"publisher","unstructured":"K. Yoshihara, M. Shahmoradgoli, E. Martinez, R. Vegesna, H. Kim, W. Torres-Garcia, et al., Inferring tumour purity and stromal and immune cell admixture from expression data, <i>Nat. Commun.<\/i>, <b>4<\/b> (2013), 2612. https:\/\/doi.org\/10.1038\/ncomms3612","DOI":"10.1038\/ncomms3612"},{"key":"key-10.3934\/mbe.2023881-35","doi-asserted-by":"publisher","unstructured":"A. Bagaev, N. Kotlov, K. Nomie, V. Svekolkin, A. Gafurov, O. Isaeva, et al., Conserved pan-cancer microenvironment subtypes predict response to immunotherapy, <i>Cancer Cell<\/i>, <b>39<\/b> (2021), 845\u2013865. https:\/\/doi.org\/10.1016\/j.ccell.2021.04.014","DOI":"10.1016\/j.ccell.2021.04.014"},{"key":"key-10.3934\/mbe.2023881-36","doi-asserted-by":"publisher","unstructured":"M. D. Wilkerson, D. N. Hayes, ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking, <i>Bioinformatics<\/i>, <b>26<\/b> (2010), 1572\u20131573. https:\/\/doi.org\/10.1093\/bioinformatics\/btq170","DOI":"10.1093\/bioinformatics\/btq170"},{"key":"key-10.3934\/mbe.2023881-37","doi-asserted-by":"publisher","unstructured":"Y. Zhou, B. Zhou, L. Pache, M. Chang, A. H. Khodabakhshi, O. Tanaseichuk, et al., Metascape provides a biologist-oriented resource for the analysis of systems-level datasets, <i>Nat. Commun.<\/i>, <b>10<\/b> (2019), 1523. https:\/\/doi.org\/10.1038\/s41467-019-09234-6","DOI":"10.1038\/s41467-019-09234-6"},{"key":"key-10.3934\/mbe.2023881-38","doi-asserted-by":"publisher","unstructured":"F. Sanchez-Vega, M. Mina, J. Armenia, W. K. Chatila, A. Luna, K. C. La, et al., Oncogenic signaling pathways in the cancer genome atlas, <i>Cell<\/i>, <b>173<\/b> (2018), 321\u2013337. https:\/\/doi.org\/10.1016\/j.cell.2018.03.035","DOI":"10.1016\/j.cell.2018.03.035"},{"key":"key-10.3934\/mbe.2023881-39","doi-asserted-by":"publisher","unstructured":"D. Hanahan, R. A. Weinberg, Hallmarks of cancer: the next generation, <i>Cell<\/i>, <b>144<\/b> (2011), 646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"key-10.3934\/mbe.2023881-40","doi-asserted-by":"publisher","unstructured":"A. Liberzon, C. Birger, H. Thorvaldsdottir, M. Ghandi, J. P. Mesirov, P. Tamayo, The Molecular Signatures Database (MSigDB) hallmark gene set collection, <i>Cell Syst.<\/i>, <b>1<\/b> (2015), 417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004","DOI":"10.1016\/j.cels.2015.12.004"},{"key":"key-10.3934\/mbe.2023881-41","doi-asserted-by":"publisher","unstructured":"S. Hanzelmann, R. Castelo, J. Guinney, GSVA: gene set variation analysis for microarray and RNA-seq data, <i>BMC Bioinf.<\/i>, <b>14<\/b> (2013), 7. https:\/\/doi.org\/10.1186\/1471-2105-14-7","DOI":"10.1186\/1471-2105-14-7"},{"key":"key-10.3934\/mbe.2023881-42","doi-asserted-by":"publisher","unstructured":"T. N. Gide, C. Quek, A. M. Menzies, A. T. Tasker, P. Shang, J. Holst, et al., Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1\/Anti-CTLA-4 combined therapy, <i>Cancer Cell<\/i>, <b>35<\/b> (2019), 238-255. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.003","DOI":"10.1016\/j.ccell.2019.01.003"},{"key":"key-10.3934\/mbe.2023881-43","doi-asserted-by":"publisher","unstructured":"T. N. Gide, J. S. Wilmott, R. A. Scolyer, G. V. Long, Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma, <i>Clin. Cancer Res.<\/i>, <b>24<\/b> (2018), 1260\u20131270. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2267","DOI":"10.1158\/1078-0432.CCR-17-2267"},{"key":"key-10.3934\/mbe.2023881-44","doi-asserted-by":"publisher","unstructured":"R. Akbani, K. C. Akdemir, B. A. Aksoy, M. Albert, A. Ally, S. B. Amin, et al., Genomic classification of cutaneous melanoma, <i>Cell<\/i>, <b>161<\/b> (2015), 1681\u20131696. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"key-10.3934\/mbe.2023881-45","doi-asserted-by":"publisher","unstructured":"T. A. Waldmann, Cytokines in Cancer Immunotherapy, <i>Cold Spring Harbor Perspect. Biol.<\/i>, <b>10<\/b> (2018). https:\/\/doi.org\/10.1101\/cshperspect.a028472","DOI":"10.1101\/cshperspect.a028472"},{"key":"key-10.3934\/mbe.2023881-46","doi-asserted-by":"publisher","unstructured":"M. Shakiba, P. Zumbo, G. Espinosa-Carrasco, L. Menocal, F. D\u00fcndar, S. E. Carson, et al., TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion, <i>J. Exp. Med.<\/i>, <b>219<\/b> (2022). https:\/\/doi.org\/10.1084\/jem.20201966","DOI":"10.1084\/jem.20201966"},{"key":"key-10.3934\/mbe.2023881-47","doi-asserted-by":"publisher","unstructured":"R. Kolb, G. Liu, A. M. Janowski, F. S. Sutterwala, W. Zhang, Inflammasomes in cancer: a double-edged sword, <i>Protein Cell<\/i>, <b>5<\/b> (2014), 12\u201320. https:\/\/doi.org\/10.1007\/s13238-013-0001-4","DOI":"10.1007\/s13238-013-0001-4"},{"key":"key-10.3934\/mbe.2023881-48","doi-asserted-by":"publisher","unstructured":"M. Okamoto, W. Liu, Y. Luo, A. Tanaka, X. Cai, D. A. Norris, et al., Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta, <i>J. Biol. Chem.<\/i>, <b>285<\/b> (2010), 6477\u20136488. https:\/\/doi.org\/10.1074\/jbc.M109.064907","DOI":"10.1074\/jbc.M109.064907"},{"key":"key-10.3934\/mbe.2023881-49","doi-asserted-by":"publisher","unstructured":"V. A. Rathinam, K. A. Fitzgerald, Inflammasome complexes: Emerging mechanisms and effector functions, <i>Cell<\/i>, <b>165<\/b> (2016), 792\u2013800. https:\/\/doi.org\/10.1016\/j.cell.2016.03.046","DOI":"10.1016\/j.cell.2016.03.046"},{"key":"key-10.3934\/mbe.2023881-50","doi-asserted-by":"publisher","unstructured":"J. M. Redman, G. T. Gibney, M. B. Atkins, Advances in immunotherapy for melanoma, <i>BMC Med.<\/i>, <b>14<\/b> (2016). https:\/\/doi.org\/10.1186\/s12916-016-0571-0","DOI":"10.1186\/s12916-016-0571-0"},{"key":"key-10.3934\/mbe.2023881-51","doi-asserted-by":"publisher","unstructured":"B. J. Schneider, J. Naidoo, B. D. Santomasso, C. Lacchetti, S. Adkins, M. Anadkat, et al., Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: Asco guideline update, <i>J. Clin. Oncol.<\/i>, <b>39<\/b> (2021), 4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","DOI":"10.1200\/JCO.21.01440"},{"key":"key-10.3934\/mbe.2023881-52","doi-asserted-by":"publisher","unstructured":"D. B. Johnson, C. A. Nebhan, J. J. Moslehi, J. M. Balko, Immune-checkpoint inhibitors: long-term implications of toxicity, <i>Nat. Rev. Clin. Oncol.<\/i>, <b>19<\/b> (2022), 254\u2013267. https:\/\/doi.org\/10.1038\/s41571-022-00600-w","DOI":"10.1038\/s41571-022-00600-w"},{"key":"key-10.3934\/mbe.2023881-53","doi-asserted-by":"publisher","unstructured":"B. Theivanthiran, N. Yarla, T. Haykal, Y. V. Nguyen, L. Cao, M. Ferreira, et al., Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy, <i>Sci. Transl. Med.<\/i>, <b>14<\/b> (2022), 7019. https:\/\/doi.org\/10.1126\/scitranslmed.abq7019","DOI":"10.1126\/scitranslmed.abq7019"},{"key":"key-10.3934\/mbe.2023881-54","doi-asserted-by":"publisher","unstructured":"J. J. Havel, D. Chowell, T. A. Chan, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, <i>Nat. Rev. Cancer<\/i>, <b>19<\/b> (2019), 133-150. https:\/\/doi.org\/10.1038\/s41568-019-0116-x","DOI":"10.1038\/s41568-019-0116-x"},{"key":"key-10.3934\/mbe.2023881-55","doi-asserted-by":"publisher","unstructured":"G. Dranoff, Cytokines in cancer pathogenesis and cancer therapy, <i>Nat. Rev. Cancer<\/i>, <b>4<\/b> (2004), 11\u201322. https:\/\/doi.org\/10.1038\/nrc1252","DOI":"10.1038\/nrc1252"}],"container-title":["Mathematical Biosciences and Engineering"],"original-title":[],"link":[{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/mbe.2023881?viewType=html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T03:09:18Z","timestamp":1698894558000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aimspress.com\/article\/doi\/10.3934\/mbe.2023881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.3934\/mbe.2023881","relation":{},"ISSN":["1551-0018"],"issn-type":[{"value":"1551-0018","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}